Cytoreductive Surgery in Advanced Endometrial Cancer

Slides:

Advertisements

Similar presentations

High Resolution data for rare cancers Annalisa Trama Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy ) WORKSHOP FOR A EUROPEAN HIGH RESOLUTION.

Advertisements

CRITICAL APPRAISAL ON AN ARTICLE ABOUT PROGNOSIS

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.

Malignant Disease Of The Uterus Dr Khalid Sait FRCSC A.Professor of Gynecological Oncology KAAUH, Jeddah( KSA)

Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.

Clinical Questions What is the superior surgical approach for postmenopausal women with early stage endometrial cancer in terms of patient quality of life?

AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)

The PAN-Care Project Development and testing of a comprehensive care planning service to enable patients with end stage pancreatic cancer die at home Department.

Are there benefits from chemotherapy to early endometrial cancer

10 Minutes Talk 吳華席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.

Information network on rare cancers RARECARENet Annalisa Trama, Gemma Gatta Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy)

ACRIN 6678 Site Training ACRIN 6678 FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung.

INT Translational research in head and neck cancer: preoperative chemotherapy in oral cavity cancer based on disease molecular profiling. Paolo Bossi MSO.

ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

Jo Anne Zujewski, MD Clinical Investigations Branch Cancer Therapy Evaluation Program Division of Cancer Diagnosis and Treatment May 2011 The Global Burden.

Intensity-Modulated Radiotherapy is Associated with Improved Global Quality of Life Among Long-Term Survivors of Head and Neck Cancer Allen M. Chen, M.D.,

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab- Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.

MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

Elderly Women Ovarian Cancer Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian.

HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.

BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.

Elderly Women Ovarian Cancer Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian.

EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed.

MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.

NEOADJUVANT CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CANCER

Savage KJ et al. Proc ASH 2015;Abstract 579.

Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.

Su K. Metcalfe, MD, MPH, Michael T

Javelin A Phase III, open-label, multicenter trial of avelumab (MSB C) versus platinum-based doublet as a first-line treatment of recurrent or.

MITO (Multicentre Italian Trials in Ovarian cancer) - CERV2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced.

Criticisms Conservative treatment of EC Limited amount of data Retrospective studies in most cases Often short follow-up Insufficient information on reproductive.

Fondazione IRCCS Istituto Nazionale Tumori

MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)

Evaluation of Response to Induction-Chemotherapy in Correlation to p53 Genotype in NSCLC stage III; Phase II Study P53 analysis OP 3 cyles GEMZAR/ CIS.

ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.

The POSITIVE study A large international research effort coordinated by International Breast Cancer Study Group (IBCSG) worldwide ALLIANCE for Clinical.

Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth Bimonte S1, Leongito M1, Barbieri.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

Broadening Eligibility Criteria to Make Clinical Trials More Representative Joint Recommendations of the American Society of Clinical Oncology and Friends.

Emergency laparoscopic stoma for obstructing colorectal cancer

Feasibility Study) PB-PG

Lo sviluppo clinico di nab-paclitaxel Discussant: Fabio Puglisi

Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:

Avastin and weekly pacLItaxel use in sEx cord-stromal ovariaN tumORs

European Urology Oncology

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

SWAG SSG Gynaecological Cancers Meeting

The DISTINCTIVE study: a biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic.

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Prospective Cohort Study of Body Image Disturbance in Surgically-Managed Head and Neck Cancer Patients Evan Graboyes MD Department of Otolaryngology-Head.

Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers.

MITO CERV …3…(?) Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer.

CoPrincipal Investigators

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Adjuvant Therapy in Melanoma

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Prospective Cohort Study of Body Image Disturbance in Surgically-Managed Head and Neck Cancer Patients Evan Graboyes MD Department of Otolaryngology-Head.

MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

International Thymic Malignancies Interest Group: A Way Forward

ประกาศกระทรวงอุตสาหกรรม ฉบับที่ 5292 (พ.ศ. 2562)

Presentation transcript:

Cytoreductive Surgery in Advanced Endometrial Cancer Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study

Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study Objectives 1 Document the treatment strategy adopted in oncology reference centers for patients with primary AEC; 2 Identify the predictors of survival; Formulate a hypothesis for selection criteria/predictive factors for successful CRS in AEC; 3 4 Explore the feasibility of a biomolecular TGCA grouping analysis (potential subsequent prospective phase to validate).

Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study Eligibility Patients with primary advanced endometrial cancer treated during the period 2005 – 2015

Inclusion criteria Exclusion criteria Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study Inclusion criteria FIGO Stage: IIIA bulky*; IIIB; IIIC1 bulky*; IIIC2 bulky*; IVA; IVB intraabdominal * diagnosed by pre-operative imaging techniques and/or intraoperatively Exclusion criteria - Age > 75; - Performance Status (ECOG) >1; - Patients treated for strictly palliative purposes; - Patients with second malignancies who had been treated by laparotomy or who had a therapy that could interfere with the treatment of AEC

Cytoreductive Surgery in Advanced Endometrial Cancer Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study An appropriate data-base has been designed and will be available online to participating centers Centralised analysis c/o NCI – Naples Data Center

Cytoreductive Surgery in Advanced Endometrial Cancer Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study Istituto Nazionale Tumori di Napoli Università di Bologna Arcispedale S. Maria Nuova, Reggio Emilia Ospedale Papa Giovanni XXIII, Bergamo Ospedale San Raffaele, Milano Università di Bari

http://www.usc-intnapoli.net Study package available on Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study Study package available on http://www.usc-intnapoli.net

Cytoreductive Surgery in Advanced Endometrial Cancer Ongoing Trial – status update Cytoreductive Surgery in Advanced Endometrial Cancer Multicenter Retrospective Study CONTACT INFORMATION STEFANO GREGGI, MD, PhD Gynecologic Oncology Surgery, Istituto Nazionale Tumori “Fondazione G. Pascale” Via M. Semmola, 80131, Naples, Italy Tel.: +39 0815903320; Fax: +39 0815903851 E‐mail: s.greggi@istitutotumori.na.it